文献速递妇产影像US

醋酸乌利司他治疗对子宫肌瘤相关症状及超声评估的子宫与肌瘤体积和血管指数的影响

Influence of Ulipristal Acetate Therapy on Uterine Fibroid-Related Symptoms and on Uterine and Fibroid Volumes and Vascularity Indices Assessed by Ultrasound.
PubMed 文献 · J Ultrasound Med · 2018-03-02

研究纳入42例有症状的绝经前子宫肌瘤女性,在醋酸乌利司他治疗前及治疗3个月后行经阴道超声检查,测量子宫体积、子宫动脉搏动指数与阻力指数及73个肌瘤的供血血管指数、位置和大小。治疗3个月后所有症状显著改善(P < .05),子宫体积缩小14%(P = .03),肌瘤体积缩小32.8%(P = .01),肌瘤血管指数均显著下降(P < .05),子宫动脉血管指数下降但未达统计学显著,5型肌瘤体积缩小幅度最大(42%,P = .03)。

要点

  • 醋酸乌利司他治疗3个月后肌瘤体积缩小32.8%、子宫体积缩小14%,肌瘤供血血管指数显著下降。
  • 5型肌瘤体积缩小幅度最大(42%),高于其他类型肌瘤(P = .03)。
  • 子宫动脉血管指数下降但未达统计学显著,肌瘤血管指数下降显著(P < .05)。

核心结论

  • 醋酸乌利司他治疗可显著改善肌瘤相关症状,并有效缩小子宫与肌瘤体积、降低肌瘤血管化;5型肌瘤似乎对治疗反应最大。

研究设计与样本

  • 研究纳入42例有症状的绝经前子宫肌瘤女性,在治疗前及醋酸乌利司他治疗3个月后行经阴道超声检查,由同一超声医师测量子宫体积、子宫动脉搏动指数与阻力指数,并记录共73个肌瘤的供血血管搏动指数与阻力指数、位置和大小。

关键影像表现/征象

  • 治疗3个月后子宫体积缩小14%(P = .03)。
  • 治疗3个月后肌瘤体积缩小32.8%(P = .01)。
  • 治疗3个月后所有肌瘤供血血管指数均显著下降(P < .05)。
  • 子宫动脉血管指数治疗后下降,但未达统计学显著。
  • 按位置分型,所有类型肌瘤体积均显著缩小,5型肌瘤缩小幅度最大(42%),高于其他类型(P = .03)。

诊断标准与关键数值

  • 子宫动脉搏动指数与阻力指数用于评估子宫动脉血管情况,治疗后下降但未达统计学显著。
  • 肌瘤供血血管搏动指数与阻力指数用于评估肌瘤血管化,治疗3个月后所有肌瘤血管指数均显著下降(P < .05)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the modifications of uterine and fibroid volume, to study Doppler changes in uterine arteries and fibroid-supplying vessels, and to assess possible symptomatic relief after 3 months of treatment with ulipristal acetate.

METHODS: Forty-two premenopausal women with symptomatic fibroids were included in the study. They were evaluated clinically for the symptoms reported and underwent ultrasound examinations before starting treatment and after 3 months of therapy with ulipristal acetate. Transvaginal scanning was performed by the same sonographer, who measured the uterine volume and uterine artery pulsatility index and resistive index. Considering that some patients had more than 1 fibroid, the vascularization (supplying vessel pulsatility and resistive indices), locations, and sizes of a total of 73 fibroids were also recorded.

RESULTS: After 3 months of ulipristal acetate, patients had a significant improvement of all symptoms (P < .05). The percentage of uterine volume reduction was 14% (P = .03), with fibroid volume reduction of 32.8% (P = .01). Uterine artery vascular indices decreased after treatment, but their reduction did not reach significant results, whereas all fibroid vascular indices decreased significantly after 3 months of ulipristal acetate (P < .05). When the fibroids were divided according to their localization, all had significant volume reduction after therapy, but type 5 had the highest decrease (42%) compared to other fibroid types (P = .03).

CONCLUSIONS: Fibroid treatment with ulipristal acetate resulted in a significant improvement of fibroid-related symptoms; moreover, it proved to be effective in decreasing both uterine and fibroid volumes and fibroid vascularization. Type 5 fibroids seem to have the most major response to treatment.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Baggio S, Pomini P, Galeone F, et al. Influence of Ulipristal Acetate Therapy on Uterine Fibroid-Related Symptoms and on Uterine and Fibroid Volumes and Vascularity Indices Assessed by Ultrasound. J Ultrasound Med. 2018. PMID: 29498074. doi:10.1002/jum.14573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。